Designed to make next-generation
sequencing accessible to more labs
With room-temperature kit storage and
shipping, Illumina's newest sequencers remove barriers to enable
more insights and discoveries
SAN
DIEGO, Oct. 9, 2024 /PRNewswire/ -- Illumina,
Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and
array-based technologies, today unveiled its MiSeq™ i100 Series of
sequencing systems, delivering unparalleled benchtop speed and
simplicity to advance next-generation sequencing (NGS) for
labs.
The two new benchtop instruments, MiSeq i100 and MiSeq i100 Plus
Systems, will empower customers to unlock powerful insights
through an affordable, comprehensive solution that is simple to
understand and use, even for those with limited NGS expertise.
Room-temperature storage and shipping enable labs to sequence on
demand, with no delays for thaw time, and same-day
sample-to-analysis.
"Our customers told us they need a faster, smaller, and
easy-to-use instrument, and that's what we're delivering with the
MiSeq i100," said Jacob Thaysen,
PhD, CEO of Illumina. "Whether you are an established
next-generation sequencing lab, or looking to start sequencing for
the first time, our latest benchtop instrument adds the
plug-and-play flexibility that today's labs are seeking."
The MiSeq i100 Series builds on the legacy of the original
benchtop MiSeq System, which Illumina customers have used since
2011 to power a host of genomic discoveries. Completely
redesigned and incorporating the groundbreaking technology and
chemistry of the NovaSeq™ X Series, the MiSeq i100 will help to
fuel the next era of genomics growth and discovery.
Key technology enhancements
The MiSeq i100 Series brings Illumina's powerful XLEAP-SBS™
chemistry innovation even further—for the first time, harnessing
the potential of room-temperature storage and shipping, which
provides customers greater flexibility in how they plan and execute
their projects while reducing their environmental impact. It offers
flexible output capabilities and comes in two configurations: the
MiSeq i100 Plus System has the full 100 million single-end reads
per run, and the MiSeq i100 System has a maximum of 25 million
single-end reads per run. Key features include:
- Room-temperature shipping and storage for reagents:
Eliminating the cold chain and allowing for greater flexibility to
sequence on demand without the need to thaw reagents, which is
critical for running urgent samples
- Sustainability: An 85% reduction in packaging waste
compared to the MiSeq System supports a lower carbon footprint
- Speed: Dramatic reduction in run times: as fast as four
hours, with same-day results (4× faster than MiSeq)
- Cost efficiency: Cost-effective consumables enable more
affordable sequencing
- Turnkey workflows: 18 proven end-to-end workflows across
10 applications
- Simplicity: Simpler, streamlined operations for various
levels of sequencing experience
Push-button workflows on MiSeq i100 are available for small
whole-genome sequencing for microbiology and targeted NGS panels
for both infectious disease and oncology. Workflows provide metrics
either directly on the instrument or via cloud-based DRAGEN™
genomic data analysis, minimizing the need for bioinformatics
expertise.
"The MiSeq i100 symbolizes Illumina's commitment to delivering
total systems with complete workflows that allow our customers to
accomplish more," said Steve
Barnard, PhD, chief technology officer of
Illumina. "With its enhanced speed, simplicity, scalability,
and quality–and its intuitive user experience–the MiSeq i100 sets a
new standard for benchtop sequencing."
Customer reactions
Illumina conducted early access testing of MiSeq i100 with
customers around the world. Geneviève DonPierre, team leader
of NGS Sequencing at Génome Québec, shared her lab's experience
with the instrument, noting that most of the sequencing operations
at the Center of Expertise and Services of Génome Québec are
conducted on the NovaSeq X Plus. "With this new instrument, we are
able to provide answers quickly for small projects or for
researchers who need fast answers to determine whether or not they
should pursue their project."
Génome Québec is a nonprofit organization that provides
genomic services for researchers in the academic and industrial
fields of 45 countries. DonPierre noted the importance of room
temperature storage for her lab: "It really helps the planning for
the sequencing run. We don't have to think two days before to get a
kit out of the freezer. So it really is a game changer to have kits
stored at room temperature."
Tim Roloff Handschin, PhD,
co-leader of Microbial Genomics (NGS) at the Institute for Medical
Microbiology at the University of Zurich, and his team conduct research on
developing new diagnostic tests, antimicrobial resistance and
antimicrobial drugs. In his lab's experience with MiSeq i100, the
ease of use and being able to achieve a turnaround time from
bacterial culture to results within 24 hours will be
transformative.
"We can start two runs on the same day and thereby increase our
sample flow massively. And given that the reagents are shipped at
room temperature, we don't need to wait for the cartridges to
thaw," Roloff said. "We can just launch a run whenever we're ready
with a new pool and there is no planning needed upfront. This gives
us great flexibility, and this can provide new possibilities to
develop new tests."
The new instrument was unveiled during a virtual customer event;
a replay may be viewed here. The MiSeq i100 will be available to
ship globally in 2025. For more information, visit the website.
Use of forward-looking statements
This release may contain forward-looking statements that involve
risks and uncertainties. Among the important factors to which our
business is subject that could cause actual results to differ
materially from those in any forward-looking statements are: (i)
challenges inherent in developing, manufacturing, and launching new
products and services; (ii) our ability to manufacture robust
instrumentation and consumables; (iii) customer uptake of, and
satisfaction with new products and services; and (iv) the speed and
scale of new product adoption by customers, together with other
factors detailed in our filings with the Securities and Exchange
Commission, including our most recent filings on Forms 10-K and
10-Q, or in information disclosed in public conference calls, the
date and time of which are released beforehand. We undertake no
obligation, and do not intend, to update these forward-looking
statements, to review or confirm analysts' expectations, or to
provide interim reports or updates on the progress of the current
quarter.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as a global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical, and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture, and other emerging segments. To
learn more, visit illumina.com and connect with us on X,
Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Salli Schwartz
858-291-6421
IR@illumina.com
Media:
Christine Douglass
PR@illumina.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/illumina-introduces-the-miseq-i100-series-its-simplest-fastest-benchtop-sequencers-302270917.html
SOURCE Illumina, Inc.